CTLA4 and neoplasm: Although CTLA-4 is known to regulate the primary immune response to antigen exposure, there is still no consensus on whether Ipi therapy enhances anti-tumor immunosurveillance by boosting pre-existing neoantigen-specific CD8+ T-cells or priming CD8+ T-cells against new tumor epitopes [26, 46, 47].